About this trial
Stroke is a leading cause of disability and the second leading cause of death worldwide. Most strokes are ischemic, caused by acute arterial occlusion. Post-stroke treatment focuses on secondary prevention and rehabilitation, but few treatments address functional recovery. Creatine, a supplement known for improving physical performance, may aid in the recovery of stroke patients, reducing sarcopenia and improving strength among other effects. This pilot study will investigate the effectiveness of creatine supplementation in enhancing physical and functional recovery in ischemic stroke patients. The study will involve a randomized, double-blind clinical trial comparing creatine monohydrate to a placebo.
Eligibility criteria
Qualifiers
Age between 18 and 80 years
Recent diagnosis of ischemic stroke (from 24 hours to 5 days) .
Neurological deficit due to the stroke that affects mobility (paresis and/or ataxia) and requires motor rehabilitation.
Ability to understand and sign the informed consent form, or failing that, have sufficient support to carry out the correct follow-up of the study.
Disqualifiers
Moderate-severe disability prior to stroke, defined by an mRS>2.
Unstable or severe clinical situation that prevents active rehabilitation.
Neurological deficit due to stroke that prevents walking without help from another person. The use of support with a cane, crutch or walker is permitted.
Moderate or severe dysphagia that makes therapeutic adherence difficult.
Trial design
Treatments tested in this trial
- Creatine monohydrate
- Placebo
Treatment groups
Sponsors and collaborators
Fundació d'investigació Sanitària de les Illes Balears
Lead sponsor
Comunidad Autónoma de las Islas Baleares (Dirección General de Investigación en Salud, Formación y Acreditación)
Collaborator